Indication
NPM1-mutated Acute Myeloid Leukemia
1 clinical trial
4 products
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid LeukemiaStatus: Terminated, Estimated PCD: 2023-03-30
Product
PlaceboProduct
EntospletinibProduct
CytarabineProduct
Anthracycline